Please login to the form below

Not currently logged in
Email:
Password:

Alexion

This page shows the latest Alexion news and features for those working in and with pharma, biotech and healthcare.

Orphan drugs dominate FDA's record-breaking year

Orphan drugs dominate FDA's record-breaking year

That included Alexion’s Ultomiris (ravulizumab) for paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disease, which according to the FDA will “change the way that patients with PNH

Latest news

  • Alexion targets RNAi with $637m Dicerna deal Alexion targets RNAi with $637m Dicerna deal

    Alexion already has a follow-on complement inhibitor to be the next generation replacement for Soliris. ... With Soliris, Alexion has demonstrated the transformative impact of complement inhibition on multiple serious and debilitating diseases.

  • Alexion adds to pipeline with $1.2bn Syntimmune buy Alexion adds to pipeline with $1.2bn Syntimmune buy

    Alexion has agreed a $1.2bn takeover of US biotech Syntimmune that will add another clinical-stage rare disease drug to its R&D pipeline. ... in the early stages of growth – Alexion has been fixated on bolstering its pipeline.

  • Abingworth raises $315m to expand hunt for promising biotechs Abingworth raises $315m to expand hunt for promising biotechs

    The acquisitions of rare disease specialist Wilson Therapeutics by Alexion for $855m and of IFM Therapeutics – an immuno-oncology player – by Bristol-Myers Squibb for $1.3bn are recent successes for

  • The year of the blockbuster The year of the blockbuster

    These include Juno Therapeutics’ CAR T-cell therapy, lisocabtagene maraleucel, for diffuse large B-cell lymphoma, and Alexion’s next-generation Soliris treatment, ravulizumab, for paroxysmal nocturnal haemoglobinuria.

  • Alexion uses priority review voucher for Soliris follow-up Alexion uses priority review voucher for Soliris follow-up

    Files ravulizumab for paroxysmal nocturnal haemoglobinuria. Alexion is pulling out all the stops to get speedy approval for a follow-up to its rare blood disorder therapy Soliris, using a coveted ... Alexion says it is planning additional regulatory

More from news
Approximately 24 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • European venture funding for the life science sector European venture funding for the life science sector

    Eli Lilly, Novartis and Alexion, should ensure a healthy M&A appetite going forward.

  • Deal Watch March 2017 Deal Watch March 2017

    In our Top 20 we have only three: Alexion in-licensed the lipid nanoparticle (LNP) technology from Arbutus Biopharma to use as a delivery technology for an mRNA rare disease product ... 90. Arbutus Biopharma. Alexion. Licence. Lipid Nanoparticle (LNP)

  • Deal Watch August 2016 Deal Watch August 2016

    This high premium and the one for Cynapsys (see below) has led to speculation that other potential target mid cap biotech companies such as Vertex, BioMarin and Alexion could command higher

  • Deal Watch October 2015 Deal Watch October 2015

    Whilst considering nucleic acid-based approaches, it was interesting to see that mRNA company Moderna Therapeutics, which has a number of deals under its belt with AstraZeneca, Alexion and Merck &Co,

  • Pharma deals in May 2015 Pharma deals in May 2015

    Topping the table with a headline value of $8.4bn was the acquisition of Synageva BioPharma by Alexion. ... With a similar headline value to Synageva/Alexion and building on its acquisition plans was the purchase of Par Pharmaceuticals by Endo.

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest appointments

  • Abeona Therapeutics names CEO Abeona Therapeutics names CEO

    Carsten Thiel joins the biopharma from Alexion. Rare genetic disease focused biopharma Abeona Therapeutics has named its chief executive officer in the form of Carsten Thiel. ... Formerly serving as Alexion Pharmaceutical’s executive vice president and

  • Amryt Pharma appoints Jordi Casals as head of Europe Amryt Pharma appoints Jordi Casals as head of Europe

    Prior to this, he worked for eight years at Alexion Pharmaceuticals, latterly as vice president commercial operations, Western Europe.

  • Alexion Pharmaceuticals adds to its board Alexion Pharmaceuticals adds to its board

    Judith Reinsdorf recently worked at Johnson Controls. Alexion Pharmaceuticals has appointed Judith Reinsdorf to its board of directors following her role as executive vice president and general counsel of Johnson Controls. ... David Brennan, chairman of

  • Alexion appoints new senior VP for EMEAC region Alexion appoints new senior VP for EMEAC region

    Camilla Harder Hartvig will lead commercial activities from Zurich, Switzerland. Alexion Pharma has appointed Camilla Harder Hartvig as its senior vice president and head of its EMEAC region. ... Alexion’s global business, and look forward to

  • Belgium's TiGenix appoints Dr Gregory Gordon Belgium's TiGenix appoints Dr Gregory Gordon

    Meanwhile, Valles-Sukkar arrives at TiGenix from Alexion Pharmaceuticals, where she was responsible for all aspects of clinical trial development.

More from appointments
Approximately 3 fully matching, plus 7 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics